During the first half of this year, Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. Roche’s MS drug Ocrevus earns blockbuster status a year after ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...

Ocrelizumab (Ocrevus), is a drug that sticks to B cells and destroys them. That helps prevent MS damage and symptoms. It’s approved by the FDA for: Clinically isolated syndrome Relapsing ...

The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus) treats relapsing forms of MS, including: Clinically isolated syndrome Relapsing-remitting MS Active secondary progressive MS in ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Roche is looking to use Dyno’s technologies to target neurological diseases, a big focus at the Swiss pharma, with multiple sclerosis blockbuster Ocrevus serving as its best-selling asset.

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

While pricing power and demand for Biogen's injectable MS portfolio are eroding in the face of new competition, Biogen receives substantial royalties on Roche's popular drug Ocrevus, which helps ...

In der dreiteiligen Doku treffen sich vier Frauen, die ein Thema vereint: die Wechseljahre. Sie sprechen darüber in der Sauna - offen, authentisch und ohne Tabus. Jede hat ihre persönliche ...